Sector News

Shire will cut U.S. locations and move HQ in consolidation push

July 5, 2017
Life sciences

Shire has decided to concentrate its U.S. operations into two main sites in Massachusetts—Cambridge and Lexington—in a move that will probably lead to the closure of some sites.

The Ireland-headquartered group employs more than 3,000 people in the state but stressed that despite the consolidation plans, it does not expect any significant reduction in overall headcount. In fact, some R&D staffers will be moved to Massachusetts from Europe and the company is expecting to make plenty of new hires in the coming years.

When the process is completed, its rare disease research and U.S. commercial operations will be based at a site in Kendall Square, Cambridge, that was formerly operated by Sanofi Genzyme and was leased last year, along with an adjacent site that put together form a 550,000-square-foot campus.

Meanwhile, Lexington—the company’s current U.S. HQ—will be the location for manufacturing of biologic drugs and the development and production of delivery systems, including digitally connected devices.

Shire is now the state’s second-largest biopharma employer, according to a Boston Globe article (sub. req.), but according to the company’s CEO Flemming Ornskov it has “a bit of a fragmented structure” there with staff “spread out in many locations” including units at Alewife, Milford, Burlington and North Reading.

Not all of the company’s Massachusetts employees are happy with the news, however, with some concerned that they will face big problems commuting into the increasingly congested Kendall Square area.

The move comes in the midst of a big transformation for Shire, which acquired both Dyax and Baxalta last year and left it with a huge task in refining its commercial structures, ushering a dramatically increased pipeline of products to market and advancing a broader R&D base with around 40 drugs in clinical development.

Shire has already started to streamline its locations in the wake of the takeovers, and is currently taking a good look at its manufacturing network, where it currently has 17 sites in seven countries and employs around 14,000 people.

Ornskov will be directly overseeing the changes—that are due to complete by mid-2019—for the time being following the departure of former R&D chief Phil Vickers, who has said he intends to step down from the position.

By Phil Taylor

Source: Fierce Biotech

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach